文献速递类风湿关节炎

丹麦和瑞典真实世界中类风湿关节炎患者使用阿巴西普、利妥昔单抗或托珠单抗的严重感染风险

Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
PubMed 文献 · Ann Rheum Dis · 2019-01-05

该观察性队列研究在丹麦和瑞典纳入2010-2015年启动阿巴西普、利妥昔单抗或托珠单抗治疗的类风湿关节炎患者,共8987个治疗疗程。结果显示三药严重感染发生率存在数值差异,调整后相对风险托珠单抗<阿巴西普<利妥昔单抗,但置信区间宽且可能残留混杂,需谨慎解读。

要点

  • 利妥昔单抗治疗者基线年龄更大、病程更长、既往恶性肿瘤更多。
  • 12个月严重感染发生率丹麦为阿巴西普7.1、利妥昔单抗8.1、托珠单抗6.1每100人年。
  • 调整后12个月相对风险托珠单抗vs利妥昔单抗合并0.78(0.61-1.01)。

核心结论

  • 三药严重感染发生率存在数值差异,相对风险似为托珠单抗<阿巴西普<利妥昔单抗,但因事件数少和残留混杂应谨慎解读。

研究设计与样本

  • 在丹麦和瑞典平行开展的观察性队列研究,纳入2010-2015年启动阿巴西普、利妥昔单抗或托珠单抗治疗的类风湿关节炎患者,共8987个治疗疗程。

主要发现

  • 12个月年龄性别调整严重感染发生率丹麦为阿巴西普7.1、利妥昔单抗8.1、托珠单抗6.1每100人年,瑞典为6.0、6.4、4.7每100人年。
  • 24个月年龄性别调整严重感染发生率丹麦为阿巴西普6.1、利妥昔单抗7.5、托珠单抗5.2每100人年,瑞典为5.6、5.8、4.3每100人年。
  • 调整后12个月相对风险托珠单抗vs利妥昔单抗丹麦0.82(0.50-1.36)、瑞典0.76(0.57-1.02)、合并0.78(0.61-1.01)。
  • 调整后12个月相对风险阿巴西普vs利妥昔单抗丹麦0.94(0.55-1.60)、瑞典0.86(0.66-1.13)、合并0.88(0.69-1.12)。
  • 调整后12个月相对风险阿巴西普vs托珠单抗丹麦1.15(0.69-1.90)、瑞典1.14(0.83-1.55)、合并1.13(0.91-1.42)。

临床怎么用

  • 真实世界启动这三种生物制剂时需注意基线特征差异,利妥昔单抗治疗者年龄更大、病程更长、既往恶性肿瘤更多。
  • 严重感染相对风险托珠单抗<阿巴西普<利妥昔单抗的数值趋势可供临床参考,但置信区间宽且可能残留混杂,不宜据此直接改变用药选择。

局限性

  • 事件数少且存在残留混杂风险,相对风险应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate (1) crude and age-and gender-adjusted incidence rates (IRs) of serious infections (SI) and (2) relative risks (RR) of SI in patients with rheumatoid arthritis (RA) initiating treatment with abatacept, rituximab or tocilizumab in routine care. METHODS: This is an observational cohort study conducted in parallel in Denmark and Sweden including patients with RA in Denmark (DANBIO) and Sweden (Anti-Rheumatic Treatment in Sweden Register/Swedish Rheumatology Quality Register) who started abatacept/rituximab/tocilizumab in 2010-2015. Patients could contribute to more than one treatment course. Incident SI (hospitalisations listing infection) and potential confounders were identified through linkage to national registries. Age- and gender-adjusted IRs of SI per 100 person years and additionally adjusted RRs of SI during 0-12 and 0-24 months since start of treatment were assessed (Poisson regression). Country-specific RRs were pooled using inverse variance weighting. RESULTS: We identified 8987 treatment courses (abatacept: 2725; rituximab: 3363; tocilizumab: 2899). At treatment start, rituximab-treated patients were older, had longer disease duration and more previous malignancies; tocilizumab-treated patients had higher C reactive protein. During 0-12 and 0-24 months of follow-up, 456 and 639 SI events were identified, respectively. The following were the age- and gender-adjusted 12-month IRs for abatacept/rituximab/tocilizumab: 7.1/8.1/6.1 for Denmark and 6.0/6.4/4.7 for Sweden. The 24-month IRs were 6.1/7.5/5.2 for Denmark and 5.6/5.8/4.3 for Sweden. Adjusted 12-month RRs for tocilizumab versus rituximab were 0.82 (0.50 to 1.36) for Denmark and 0.76 (0.57 to 1.02) for Sweden, pooled 0.78 (0.61 to 1.01); for abatacept versus rituximab 0.94 (0.55 to 1.60) for Denmark and 0.86 (0.66 to 1.13) for Sweden, pooled 0.88 (0.69 to 1.12); and for abatacept versus tocilizumab 1.15 (0.69 to 1.90) for Denmark and 1.14 (0.83 to 1.55) for Sweden, pooled 1.13 (0.91 to 1.42). The adjusted RRs for 0-24 months were similar. CONCLUSION: For patients starting abatacept, rituximab or tocilizumab, differences in baseline characteristics were seen. Numerical differences in IR of SI between drugs were observed. RRs seemed to vary with drug (tocilizumab < abatacept < rituximab) but should be interpreted with caution due to few events and risk of residual confounding.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Grøn KL, Arkema EV, Glintborg B, et al. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Ann Rheum Dis. 2019. PMID: 30612115. doi:10.1136/annrheumdis-2018-214326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。